HTG Expands Therapeutics Team
“Dr. Carruthers has an extensive background in the pharmaceutical and biotech industries, with her experiences spanning drug discovery, early development, registration and due diligence supporting pipeline development through partnerships and acquisitions,” said Dr.
“New therapeutic approaches grounded in RNA either as target or modality have the potential to reform our thinking on how to understand and ultimately treat diseases. I believe HTG’s proprietary technologies will undoubtedly play a key role in this area of scientific advancement and I’m very excited to become a member of this dynamic team,” said
A video providing an overview of HTG’s Therapeutics Division is available on the company’s website.
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding HTG’s proprietary RNA platform potentially disrupting the traditional drug discovery process and bringing innovative small molecule therapeutic candidates forward, HTG’s proprietary technologies playing a key role in new therapeutic approaches grounded in RNA either as target or modality, the benefits of HTG’s RNA platform and other potential benefits of HTG’s RNA platform and technologies. Words such as “believes,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with drug discovery and development; the risk that our RNA platform and medicinal chemistry technologies may not provide the benefits that we expect; risks associated with our ability to develop and commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; risks associated with the impact of the COVID-19 pandemic on us and our customers; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission (SEC), including under the “Risk Factors” heading of our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.